Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZ/SAR402671 (venglustat) in early-stage Parkinson's disease with GBA mutation
2016-000657-12Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Venglustat with Placebo (2 arms). Primary endpoint: Part 1: Safety and tolerability. Started Oct 2016; status: terminated.
02
Drugs
venglustat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-000657-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000657-12.